Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907205 | 0.76 | ALDH1A1 (0.54) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL10720045 | 0.76 | ALDH1A1 (0.54) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6120718 | 0.73 | MIF (0.49) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13186559 | 0.73 | MIF (0.61) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12341036 | 0.72 | MIF (0.47) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13482509 | 0.72 | MIF (0.47) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12343965 | 0.72 | NPC1 (0.55) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL397884 | 0.71 | ALDH1A1 (0.65) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6717566 | 0.71 | NPC1 (0.64) | MIFGABRA1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL25007628 | 0.71 | ALDH1A1 (0.50) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020193802-A1 | POLYMERIC CONJUGATES AND USES THEREOF | FUNDACIÓN DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE (ES) | 2020-10-01 | — | — | WO | disclosed |
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | disclosed |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| EP-2640712-B1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2018-02-01 | — | — | US | disclosed |
| US-20170231932-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | AmDerma Pharmaceuticals, LLC | 2017-08-17 | — | — | US | disclosed |
| US-9610256-B2 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer | AmDerma Pharmaceuticals, LLC (US) | 2017-04-04 | — | — | US | disclosed |
| US-9592216-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2006052899-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006041855-A2 | COMPOSITIONS AND METHODS USING APOCYNIN COMPOUNDS AND NITRIC OXIDE DONORS | NITROMED, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005107384-A2 | METHODS FOR TREATING BLOOD DISORDERS WITH NITRIC OXIDE DONOR COMPOUNDS | NITROMED, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005070006-A2 | NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005060603-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005018561-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | MIF 4233/4885GABRA1 1999/4885ALDH1A1 15/4885 |
| US-10278940-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | CYP8B1, CYP26B1, CYP24A1 | MIF 3501/4885GABRA1 2880/4885ALDH1A1 101/4885 |
| US-20170231932-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | IL2, IL2RA, IL5 | MIF 2791/4885GABRA1 2515/4885ALDH1A1 843/4885 |
| US-20190192474-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | MIF 3501/4885GABRA1 2880/4885ALDH1A1 101/4885 |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | MIF 1048/4885GABRA1 3768/4885ALDH1A1 396/4885 |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | MIF 4233/4885GABRA1 1999/4885ALDH1A1 15/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | MIF 3090/4885GABRA1 1191/4885ALDH1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.